JP7546037B2 - 可溶型ｃｌｅｃ－２と血小板数に基づく血小板活性化測定方法 - Google Patents

可溶型ｃｌｅｃ－２と血小板数に基づく血小板活性化測定方法 Download PDF

Info

Publication number
JP7546037B2
JP7546037B2 JP2022503738A JP2022503738A JP7546037B2 JP 7546037 B2 JP7546037 B2 JP 7546037B2 JP 2022503738 A JP2022503738 A JP 2022503738A JP 2022503738 A JP2022503738 A JP 2022503738A JP 7546037 B2 JP7546037 B2 JP 7546037B2
Authority
JP
Japan
Prior art keywords
concentration
platelet count
platelet
clec
soluble clec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022503738A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021172493A1 (https=
Inventor
宏恭 石倉
雅英 川村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHC Corp
Original Assignee
PHC Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHC Corp filed Critical PHC Corp
Publication of JPWO2021172493A1 publication Critical patent/JPWO2021172493A1/ja
Application granted granted Critical
Publication of JP7546037B2 publication Critical patent/JP7546037B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2022503738A 2020-02-28 2021-02-26 可溶型ｃｌｅｃ－２と血小板数に基づく血小板活性化測定方法 Active JP7546037B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020032797 2020-02-28
JP2020032797 2020-02-28
PCT/JP2021/007273 WO2021172493A1 (ja) 2020-02-28 2021-02-26 可溶型ｃｌｅｃ－２と血小板数に基づく血小板活性化測定方法

Publications (2)

Publication Number Publication Date
JPWO2021172493A1 JPWO2021172493A1 (https=) 2021-09-02
JP7546037B2 true JP7546037B2 (ja) 2024-09-05

Family

ID=77491232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503738A Active JP7546037B2 (ja) 2020-02-28 2021-02-26 可溶型ｃｌｅｃ－２と血小板数に基づく血小板活性化測定方法

Country Status (6)

Country Link
US (1) US12590978B2 (https=)
EP (1) EP4113524A4 (https=)
JP (1) JP7546037B2 (https=)
KR (1) KR20220147624A (https=)
CN (1) CN115190973B (https=)
WO (1) WO2021172493A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4279606A4 (en) * 2021-01-13 2024-12-18 PHC Corporation Method for predicting risk for thrombosis in cancer patient using soluble clec2
EP4350350A4 (en) * 2021-05-31 2025-04-30 PHC Corporation METHOD FOR ASSESSING THE RISK OF HEMORRHAGIC STROKE USING SOLUBLE CLEC2
US20240264174A1 (en) * 2021-05-31 2024-08-08 Phc Corporation Method for evaluating risk of acute cerebral vascular disease using soluble clec2
WO2025075139A1 (ja) * 2023-10-06 2025-04-10 Ｐｈｃ株式会社 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013228229A (ja) 2012-04-24 2013-11-07 Chiba Univ 心血管イベントの発症リスクの検査方法
WO2013168602A1 (ja) 2012-05-07 2013-11-14 三菱化学メディエンス株式会社 播種性血管内凝固症候群または感染性播種性血管内凝固症候群を検出する方法
JP2014070942A (ja) 2012-09-28 2014-04-21 Mitsubishi Chemical Medience Corp 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法
JP2014520123A (ja) 2011-06-17 2014-08-21 アムジエン・インコーポレーテツド Ｃｌｅｃ−２を使用して代謝性障害を治療または改善させる方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297508A1 (en) 2005-04-25 2009-12-03 University Of Yamanashi Compositions and methods for treating hemostasis disorders associated with clec-2 signal transduction
JP2007070359A (ja) 2005-09-06 2007-03-22 Univ Of Yamanashi 止血疾患治療用の医薬組成物
KR20070070359A (ko) 2005-12-29 2007-07-04 삼성전자주식회사 액정표시장치
KR101399608B1 (ko) 2007-07-27 2014-05-26 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치의 제작방법
WO2010058412A1 (en) * 2008-11-19 2010-05-27 Dilip Shrinivas Velaskar A new rapid thrombochek test kit based on whole blood screening test to detect platelet hyperaggregation at a temparature of 37°c in the clinical laboratory

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520123A (ja) 2011-06-17 2014-08-21 アムジエン・インコーポレーテツド Ｃｌｅｃ−２を使用して代謝性障害を治療または改善させる方法
JP2013228229A (ja) 2012-04-24 2013-11-07 Chiba Univ 心血管イベントの発症リスクの検査方法
WO2013168602A1 (ja) 2012-05-07 2013-11-14 三菱化学メディエンス株式会社 播種性血管内凝固症候群または感染性播種性血管内凝固症候群を検出する方法
JP2014070942A (ja) 2012-09-28 2014-04-21 Mitsubishi Chemical Medience Corp 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FEI, Min et al.，Plasma soluble C-type lectin-like receptor-2 is associated with the risk of coronary artery disease，Frontiers of Medicine，2020年，vo.14, no.1，pp.81-90，doi.org/10.1007/s11684-019-0692-x
FEI, Min et al.，The production of soluble C-type lectin-like receptor 2 is a regulated process，Glycoconjugate Journal，2012年，vol.12，pp.315-321
INOUE, Osamu et al.，Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with solible GPVI，International Journal of Hematology，2019年，vol.110，pp.285-294，doi.org/10.1007/s12185-019-02680-4
YAMASHITA, Yoshiki et al.，Elevated plasma levels of soluble C-type lectin-like receptor 2 (CLEC2) in patients with thrombotic microangiopathy，Thrombosis Research，2019年，vol.178，pp.54-58，doi.org/10.1016/j.thromres.2019.03.018
八木 高秀 ほか，本態性高血圧症およびSHRSPにおける病気進展と平均血小板容積，血小板数の変動，近畿大医誌，1985年，vol.10, no.1，pp.17-24
石倉 宏恭 他，O-028 敗血症患者における新規血小板活性化マーカー可溶性CLEC2の血中動態，日本血栓止血学会誌，2020年，vol.31, no.2，p.224

Also Published As

Publication number Publication date
US12590978B2 (en) 2026-03-31
US20230168260A1 (en) 2023-06-01
CN115190973B (zh) 2025-10-21
EP4113524A4 (en) 2024-03-06
WO2021172493A1 (ja) 2021-09-02
KR20220147624A (ko) 2022-11-03
CN115190973A (zh) 2022-10-14
JPWO2021172493A1 (https=) 2021-09-02
EP4113524A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
JP7546037B2 (ja) 可溶型ｃｌｅｃ－２と血小板数に基づく血小板活性化測定方法
CN103403549B (zh) 败血症的预后的预测方法
JP4733326B2 (ja) 患者サンプル中の止血機能障害の存在を予測する方法
CN104285148B (zh) 检测弥散性血管内凝血或感染性弥散性血管内凝血的方法
JP2009539080A (ja) 急性冠状動脈症候群のリスクを有する個体の識別のためのｍｒｐ８／１４レベルの使用
Liu Changes and significance of serum CXCL-16, GDF-15, PLA-2 levels in patients with cerebral infarction
EP4636404A2 (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
EP4350350A1 (en) Method for assessing risk of hemorrhagic stroke using soluble clec2
JPWO2022255348A5 (https=)
HK40085757A (en) Method for measuring platelet activation based on soluble clec-2 and platelet count
KR20140023260A (ko) Cartilage Acidic Protein 1 단백질에 의한 뇌경색의 검사 방법
JP7808059B2 (ja) 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法
WO2025075139A1 (ja) 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法
JP7695113B2 (ja) 可溶型ｃｌｅｃ２を用いたウイルス性肺炎のリスク評価法
RU2789822C1 (ru) Способ оптимизации лабораторной диагностики тромбинемии у пациентов с инфекцией COVID-19
HK40127498A (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
HK40105374A (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
Ateş et al. The Association Between Mean Neutrophil Volume and Dipping Status in Newly Diagnosed Hypertensive Patients
HK40106384A (en) Method for assessing risk of hemorrhagic stroke using soluble clec2
CN118813790A (zh) 一种用于糖尿病足诊断的fgf-5生物标志物及其应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230501

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20240205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240826

R150 Certificate of patent or registration of utility model

Ref document number: 7546037

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150